Status:

COMPLETED

Study Evaluating rhMBP-2/CPM in Open Wedge Osteotomies

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions:

Osteoarthritis

Eligibility:

All Genders

45-70 years

Phase:

PHASE1

Brief Summary

To assess the feasibility of using rhBMP-2/CPM in OWO as a surgical model for pharmacodynamic studies, with assessment of the following parameters: * Injecting the desired volume of rhBMP-2/CPM withi...

Eligibility Criteria

Inclusion

  • Male or female subjects 45 to 70 years of age
  • Within 96 hours prior to dosing, the subject underwent a successful open wedge tibial osteotomy to correct medial compartment OA of the knee.
  • Female subjects of childbearing potential must have a negative pregnancy test (hospital acceptable test), upon hospitalization for OWO and agree to use medically approved contraception for the duration of the study.
  • Other inclusion applies.

Exclusion

  • Subjects with pre-existing conditions of the knee or tibia that would confound an interpretation of results.
  • Subjects for whom surgery in the opposite knee is planned during the 6 months of follow-up.
  • Subjects with a history of malignancy or radiotherapy or chemotherapy for malignancy within the past 5 years, except subjects with a history of basal skin carcinoma.
  • Other exclusion applies.

Key Trial Info

Start Date :

November 1 2003

Trial Type :

INTERVENTIONAL

End Date :

March 1 2005

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT00243295

Start Date

November 1 2003

End Date

March 1 2005

Last Update

October 6 2006

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.